YARGESA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug YARGESA contains one active pharmaceutical ingredient (API):

1 Miglustat UNII ADN3S497AZ - MIGLUSTAT

Miglustat is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids, and a pharmacokinetic enzyme stabiliser of cipaglucosidase alfa. Miglustat is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease and for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease. Also, miglustat must be used in combination with cipaglucosidase alfa for long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency). Read about Miglustat

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
YARGESA Hard capsule	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AX06	Miglustat	A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1742486
Country: FR	Base de données publique des médicaments	Identifier(s): 68836272
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 387358
Country: IT	Agenzia del Farmaco	Identifier(s): 045318019
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1082617
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100386829